Hinge Health (HNGE) News Today

Hinge Health Inc. (NYSE:HNGE) shares rose today after a wave of analyst upgrades and strong quarterly results. Multiple firms boosted their price targets following the company’s impressive Q2 revenue growth, while the stock also hit a fresh 52-week high.

• Positive Sentiment: Canaccord Genuity Group raised its target price to $61.00 from $52.00 and reiterated a “buy” rating. Hinge Health (NYSE:HNGE) Price Target Raised to $61.00 at Canaccord Genuity Group
• Positive Sentiment: JMP Securities lifted its target to $65.00 (from $58.00) with a “market outperform” rating. JMP Securities Raises Hinge Health (NYSE:HNGE) Price Target to $65.00
• Positive Sentiment: Barclays boosted its objective to $62.00 (from $51.00) and maintained an “overweight” stance. Barclays Boosts Hinge Health (NYSE:HNGE) Price Target to $62.00
• Positive Sentiment: Evercore ISI raised its target to $60.00 (from $50.00) with an “outperform” rating. Evercore ISI Issues Positive Forecast for Hinge Health (NYSE:HNGE) Stock Price
• Positive Sentiment: Needham & Company increased its objective to $59.00 (from $47.00) and reaffirmed a “buy” rating. Needham & Company LLC Forecasts Strong Price Appreciation for Hinge Health (NYSE:HNGE) Stock
• Positive Sentiment: Bank of America boosted its target to $64.00 (from $42.00) and maintained a “buy” rating. Bank of America Issues Positive Forecast for Hinge Health (NYSE:HNGE) Stock Price
• Positive Sentiment: Shares hit a new 52-week high after the latest round of analyst upgrades. Hinge Health (NYSE:HNGE) Hits New 52-Week High After Analyst Upgrade
• Positive Sentiment: Q2 revenue jumped 55% year-over-year, marking a strong post-IPO performance. Hinge Health reports 55% revenue increase in Q2 2025
• Positive Sentiment: The company beat Wall Street’s revenue expectations in its first public earnings release. Hinge Health beats Wall Street expectations on revenue in first public earnings
• Positive Sentiment: Free cash flow also surged following the IPO, reinforcing the strong growth narrative. Hinge Health reports 55% revenue growth in first quarter following IPO
• Positive Sentiment: Analysts highlight over 50% growth since the IPO, driving renewed investor interest. Why Hinge Health, The IPO Stock With 52% Growth, Is On The Rise Again
• Neutral Sentiment: Morgan Stanley raised its price objective to $57.00 (from $46.00) with an “overweight” rating. Morgan Stanley Issues Positive Forecast for Hinge Health (NYSE:HNGE) Stock Price